Patent Linkage Systems

Introduction

A patent linkage system is a legal and regulatory mechanism that connects the patent status of a pharmaceutical product with the approval of a generic drug for manufacture or marketing. Under this system, a drug regulatory authority may be required to consider existing patent rights before granting marketing approval to a competing product.

Patent linkage is particularly important in pharmaceutical and biotechnology industries because it attempts to balance two objectives: protecting research-based innovation and ensuring timely access to affordable medicines. In India, the issue has been examined primarily through the relationship between the Patents Act, 1970, and the Drugs and Cosmetics Act, 1940.

1. Meaning and Objectives

Patent linkage generally connects the patent register or patent information system with the drug approval process. Its principal objectives are:

To protect pharmaceutical patent holders against unauthorised commercial exploitation.

To reduce disputes concerning generic entry before patent expiry.

To provide a mechanism for identifying potentially conflicting patents.

To balance incentives for pharmaceutical research with public access to medicines.

However, patent linkage can delay generic competition if regulatory approval is withheld merely because a patent exists, even where its validity or infringement is disputed.

2. Legal Position in India

India does not recognise a general patent linkage system under its existing statutory framework. The Patents Act, 1970, governs patent grants and enforcement, while the Drugs and Cosmetics Act, 1940, regulates drug safety, quality and marketing approvals.

Section 48 of the Patents Act provides the exclusive rights of a patentee, while Section 107A establishes certain exceptions, including qualifying acts undertaken for regulatory submissions. The drug regulator's responsibility to assess safety and regulatory compliance does not automatically make it responsible for deciding patent infringement.

Indian Kanoon

+1

3. Important Case Laws

A. Bayer Corporation v. Union of India, 2010

The Delhi High Court rejected Bayer's attempt to prevent the drug regulator from considering a generic manufacturer's marketing approval application for a drug covered by Bayer's patent. The Court held that the Patents Act and the Drugs and Cosmetics Act serve distinct purposes and that patent linkage could not be inferred from the existing statutory provisions.

Legal principle: In India, a pharmaceutical patent does not automatically require the drug regulator to refuse marketing approval to a generic applicant. Patent enforcement must be pursued through legally appropriate mechanisms.

Indian Kanoon

+1

B. Bayer Corporation v. Union of India, 2019

The Delhi High Court considered the scope of Section 107A, commonly known as the Bolar provision, in disputes involving Bayer, Natco and Alembic. The litigation concerned the use of patented pharmaceutical products for regulatory purposes, including export-related activities.

Legal principle: Patent protection must be interpreted alongside statutory exceptions that facilitate regulatory approval and generic drug development. The judgment illustrates that patent rights do not automatically prohibit every activity involving a patented pharmaceutical product.

Indian Kanoon

+1

4. Advantages and Disadvantages

Patent linkage may help patent owners identify potential infringement and encourage pharmaceutical research. Conversely, it may delay affordable generic medicines, increase litigation, and allow questionable patents to obstruct market competition. Its design therefore requires safeguards against unnecessary regulatory barriers.

Conclusion

Patent linkage systems connect pharmaceutical patent rights with regulatory approval procedures. Although such systems operate in some jurisdictions, India does not recognise a general patent linkage requirement under its existing statutory framework. The Bayer Corporation v. Union of India decisions demonstrate the separation between patent enforcement and drug regulatory approval. An effective pharmaceutical legal framework must protect valid patents while preserving competition, statutory regulatory exceptions and public access to affordable medicines.